non-small cell lung cancer (NSCLC) – pharmaceutical daily

Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm

June 26, 2020June 26, 2020 GlobeNewswire 0 Comments non-small cell lung cancer (NSCLC), oncology, Roche

today announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for non-small cell lung cancer (NSCLC).

news North America

Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

May 29, 2020May 29, 2020 GlobeNewswire 0 Comments Alecensa, non-small cell lung cancer (NSCLC), oncology, Roche

ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five

news

New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC

May 13, 2020May 14, 2020 BusinessWire 0 Comments Keytruda, Merck, non-small cell lung cancer (NSCLC)

First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA Plus Concurrent Chemoradiation Achieved Objective Response Rate of 67.0%

news North America

AstraZeneca posts positive positive progression-free survival (PFS) results in phase III Poseidon trial for 1st-line treatment of stage IV non-small cell lung cancer

October 28, 2019October 28, 2019 BusinessWire 0 Comments AstraZeneca, Imfinzi, non-small cell lung cancer (NSCLC)

AstraZeneca announced Monday that Imfinzi (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line

news North America

Biodesix new clinical data shows VeriStrat testing predicts survival in advanced NSCLC and immunotherapy

September 18, 2019September 18, 2019 BusinessWire 0 Comments Biodesix, non-small cell lung cancer (NSCLC), VeriStrat

Biodesix’s positive Results from Multiple Studies Support Clinical Utility of VeriStrat Testing

Europe news

Roche’s Tecentriq shows survival benefit over chemotherapy as an initial treatment in NSCLC

September 12, 2019September 12, 2019 Dino Mustafić 0 Comments atezolizumab, non-small cell lung cancer (NSCLC), Roche, Tecentriq

Roche’s study met a goal, comparing a lung cancer therapy Tecentriq with cisplatin and pemetrexed as the initial monotherapy compared in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT).

news North America

Bristol-Myers Squibb: Long term survival with Opdivo in certain NSCLC tops traditional chemotherapy

September 10, 2019September 10, 2019 BusinessWire 0 Comments Bristol-Myers Squibb, nivolumab, non-small cell lung cancer (NSCLC), Opdivo

Longest survival follow-up from a pooled analysis of randomized Phase 3 trials of an Immuno-Oncology therapy in this setting demonstrated

news North America

Lilly soon seeks regulatory approval for RET fusion-positive NSCLC treatment

September 9, 2019September 9, 2019 Dino Mustafić 0 Comments Eli Lilly, non-small cell lung cancer (NSCLC), selpercatinib

Eli Lilly’s test of oral selpercatinib monotherapy for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) saw a 68 percent objective response rate (ORR), and also showed that safety analysis of all 531 patients enrolled to LIBRETTO-001, selpercatinib was well-tolerated, with only 9 patients (1.7%) discontinuing therapy due to treatment-related toxicity.

Asia news North America

Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

April 1, 2019April 1, 2019 BusinessWire 0 Comments Chemoterapy, Keytruda, Merck, non-small cell lung cancer (NSCLC), pembrolizumab

KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a

Approval news

Mirati and BMS to combine sitravatinib and nivolumab for certain non-small cell lung cancer patients in Mirati’s expected Phase 3 trial

January 7, 2019January 7, 2019 Dino Mustafić 0 Comments nivolumab, non-small cell lung cancer (NSCLC), NSCLC, oncology, Opdivo

Mirati Therapeutics and Bristol-Myers Squibb will work together on evaluating the combination of sitravatinib and nivolumab (OPDIVO), in Mirati’s planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.

← Previous